AbbVie’s immunology franchise, anchored by Rinvoq (upadacitinib), continues to drive top-line momentum heading into Q2 2026 results expected July 31. Global Rinvoq net revenues reached $2.119 billion in Q1 2026, up 23.3% year-over-year on a reported basis (20.2% operational), following full-year 2025 sales of $8.304 billion and sequential quarterly prints of $2.028–$2.374 billion. Management raised 2026 Rinvoq guidance to $10.2 billion alongside Skyrizi, implying sustained double-digit growth from new indications, share gains in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease, and limited near-term competition. Traders will focus on whether Q2 volumes sustain this trajectory amid typical seasonality, any pipeline or regulatory updates, and potential guidance revisions that could influence full-year consensus.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoNUEVO
31 jul 2026
$2.3 mil millones
50%
$2.4 mil millones
50%
$2.5 mil millones
50%
$2.6 mil millones
50%
$2.7 mil millones
50%
$0.00 Vol.
$2.3 mil millones
$0 Vol.
50%
$2.4 mil millones
$0 Vol.
50%
$2.5 mil millones
$0 Vol.
50%
$2.6 mil millones
$0 Vol.
50%
$2.7 mil millones
$0 Vol.
50%
This market will resolve to "Yes" if AbbVie's Global Rinvoq net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s immunology franchise, anchored by Rinvoq (upadacitinib), continues to drive top-line momentum heading into Q2 2026 results expected July 31. Global Rinvoq net revenues reached $2.119 billion in Q1 2026, up 23.3% year-over-year on a reported basis (20.2% operational), following full-year 2025 sales of $8.304 billion and sequential quarterly prints of $2.028–$2.374 billion. Management raised 2026 Rinvoq guidance to $10.2 billion alongside Skyrizi, implying sustained double-digit growth from new indications, share gains in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease, and limited near-term competition. Traders will focus on whether Q2 volumes sustain this trajectory amid typical seasonality, any pipeline or regulatory updates, and potential guidance revisions that could influence full-year consensus.
This market will resolve to "Yes" if AbbVie's Global Rinvoq net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Mercado abierto: Jul 18, 2026, 4:42 PM ET
Volumen
$0Fecha de finalización
31 jul 2026Mercado abierto
Jul 18, 2026, 4:42 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if AbbVie's Global Rinvoq net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.AbbVie’s immunology franchise, anchored by Rinvoq (upadacitinib), continues to drive top-line momentum heading into Q2 2026 results expected July 31. Global Rinvoq net revenues reached $2.119 billion in Q1 2026, up 23.3% year-over-year on a reported basis (20.2% operational), following full-year 2025 sales of $8.304 billion and sequential quarterly prints of $2.028–$2.374 billion. Management raised 2026 Rinvoq guidance to $10.2 billion alongside Skyrizi, implying sustained double-digit growth from new indications, share gains in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease, and limited near-term competition. Traders will focus on whether Q2 volumes sustain this trajectory amid typical seasonality, any pipeline or regulatory updates, and potential guidance revisions that could influence full-year consensus.
This market will resolve to "Yes" if AbbVie's Global Rinvoq net revenues for the upcoming second fiscal quarter, as reported in its official company earnings materials, are above the listed amount. Otherwise, this market will resolve to "No".
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered.
If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No".
If the specified company does not release quarterly earnings materials for the specified quarter by August 31, 2026, 11:59 PM ET, this market will resolve to "No".
If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market.
The resolution source for this market is the specified company's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used.
Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.
Volumen
$0Fecha de finalización
31 jul 2026Mercado abierto
Jul 18, 2026, 4:42 PM ETResolver
0x65070BE91...AbbVie’s immunology franchise, anchored by Rinvoq (upadacitinib), continues to drive top-line momentum heading into Q2 2026 results expected July 31. Global Rinvoq net revenues reached $2.119 billion in Q1 2026, up 23.3% year-over-year on a reported basis (20.2% operational), following full-year 2025 sales of $8.304 billion and sequential quarterly prints of $2.028–$2.374 billion. Management raised 2026 Rinvoq guidance to $10.2 billion alongside Skyrizi, implying sustained double-digit growth from new indications, share gains in rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease, and limited near-term competition. Traders will focus on whether Q2 volumes sustain this trajectory amid typical seasonality, any pipeline or regulatory updates, and potential guidance revisions that could influence full-year consensus.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes